Added to YB: 2025-04-30
Pitch date: 2025-03-11
STOK [bullish]
Stoke Therapeutics, Inc.
+299.88%
current return
Author Info
No bio for this author
Company Info
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Market Cap
$1.5B
Pitch Price
$8.25
Price Target
N/A
Dividend
N/A
EV/EBITDA
38.17
P/E
38.72
EV/Sales
5.79
Sector
Biotechnology
Category
growth
Stoke Therapeutics, Inc. - $STOK
STOK: Zorevunersen for Dravet Syndrome at discount due to catalyst desert (no Ph3 data until 2027). High PoS asset showing >50% seizure reduction at 70mg dose, potential cognitive benefits. Biogen deal provides $165M upfront + 30% Ph3 costs. $500M market cap vs potential $1B+ peak sales. 3x revenue valuation with PRV upside.
Read full article (6 min)